A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”

Benjamin Z. Leder, Bart Clarke, Elizabeth Shane, Sundeep Khosla, Douglas P. Kiel

Research output: Contribution to journalArticle

Abstract

The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled “Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention” designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on “gaps” in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment.

Original languageEnglish (US)
JournalJournal of Bone and Mineral Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Osteoporotic Fractures
National Institutes of Health (U.S.)
Osteoporosis
Drug Therapy
Research
Knowledge Bases
Therapeutics
Public Health
Education

Keywords

  • FRACTURE PREVENTION
  • OSTEOPOROSIS
  • OSTEOPOROSIS DRUG THERAPY

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

@article{72e3de3d6bfa437a83c475b4e351b2c6,
title = "A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”",
abstract = "The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled “Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention” designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on “gaps” in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment.",
keywords = "FRACTURE PREVENTION, OSTEOPOROSIS, OSTEOPOROSIS DRUG THERAPY",
author = "Leder, {Benjamin Z.} and Bart Clarke and Elizabeth Shane and Sundeep Khosla and Kiel, {Douglas P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jbmr.3823",
language = "English (US)",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A Lot of Progress, With More to Be Done

T2 - A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”

AU - Leder, Benjamin Z.

AU - Clarke, Bart

AU - Shane, Elizabeth

AU - Khosla, Sundeep

AU - Kiel, Douglas P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled “Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention” designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on “gaps” in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment.

AB - The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled “Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention” designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on “gaps” in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment.

KW - FRACTURE PREVENTION

KW - OSTEOPOROSIS

KW - OSTEOPOROSIS DRUG THERAPY

UR - http://www.scopus.com/inward/record.url?scp=85070472732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070472732&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3823

DO - 10.1002/jbmr.3823

M3 - Article

C2 - 31237962

AN - SCOPUS:85070472732

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

ER -